{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:12:38Z","timestamp":1768734758123,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00843-1","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T17:02:03Z","timestamp":1703264523000},"page":"290-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of switching from agalsidase\u2212\u03b1 to agalsidase\u2212\u03b2 on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-4735","authenticated-orcid":false,"given":"Hisato","family":"Shima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Minakuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"843_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"key":"843_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","volume":"399","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, et al. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun. 2010;399:716\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"843_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120:57\u201361.","journal-title":"Mol Genet Metab"},{"key":"843_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2215\/CJN.06090809","volume":"5","author":"R Schiffmann","year":"2010","unstructured":"Schiffmann R, Waldek S, Benigni A, Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5:360\u20134.","journal-title":"Clin J Am Soc Nephrol"},{"key":"843_CR5","doi-asserted-by":"crossref","first-page":"100983","DOI":"10.1016\/j.ymgmr.2023.100983","volume":"36","author":"K Nakamura","year":"2023","unstructured":"Nakamura K, Mukai S, Takezawa Y, Natori Y, Miyazaki A, Ide Y, et al. Clinical utility of urinary mulberry bodies\/cells testing in the diagnosis of Fabry disease. Mol Genet Metab Rep. 2023;36:100983.","journal-title":"Mol Genet Metab Rep"},{"key":"843_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ndt\/gfaa298","volume":"37","author":"H Yonishi","year":"2021","unstructured":"Yonishi H, Namba-Hamano T, Hamano T, Hotta M, Nakamura J, Sakai S, et al. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Nephrol Dial Transplant. 2021;37:53\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"843_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int"},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"843_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22:843\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"843_CR10","doi-asserted-by":"crossref","first-page":"100804","DOI":"10.1016\/j.ymgmr.2021.100804","volume":"29","author":"T Shiga","year":"2021","unstructured":"Shiga T, Tsukimura T, Namai Y, Togawa T, Sakuraba H. Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease. Mol Genet Metab Rep. 2021;29:100804.","journal-title":"Mol Genet Metab Rep"},{"key":"843_CR11","doi-asserted-by":"crossref","first-page":"100650","DOI":"10.1016\/j.ymgmr.2020.100650","volume":"25","author":"T Tsukimura","year":"2020","unstructured":"Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;25:100650.","journal-title":"Mol Genet Metab Rep"},{"key":"843_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"PB Deegan","year":"2012","unstructured":"Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35:227\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"843_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108:132\u20137.","journal-title":"Mol Genet Metab"},{"key":"843_CR14","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease. J Am Soc Nephrol. 2018;29:2265\u201378.","journal-title":"J Am Soc Nephrol"},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","volume":"59","author":"A Nowak","year":"2022","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2022;59:287\u201393.","journal-title":"J Med Genet"},{"key":"843_CR16","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neusser LP, Rudnicki M, Nordbeck P, Canaan-Kuhl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","volume":"58","author":"M Lenders","year":"2021","unstructured":"Lenders M, Nordbeck P, Canaan-Kuhl S, Kreul L, Duning T, Lorenz L, et al. Treatment switch in Fabry disease- a matter of dose? J Med Genet. 2021;58:342\u201350.","journal-title":"J Med Genet"},{"key":"843_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biom11020271","volume":"11","author":"K Kok","year":"2021","unstructured":"Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry disease: Molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules. 2021;11:271.","journal-title":"Biomolecules"},{"key":"843_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/ijms22010206","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D. Fabry disease therapy: state-of-the-art and current challenges. Int J Mol Sci. 2020;22:206.","journal-title":"Int J Mol Sci."},{"key":"843_CR20","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933\u201346.","journal-title":"Kidney Int"},{"key":"843_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13730-020-00463-z","volume":"9","author":"H Shimohata","year":"2020","unstructured":"Shimohata H, Yamashita M, Ohgi K, Maruyama H, Takayasu M, Hirayama K, et al. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy. CEN Case Rep. 2020;9:237\u201342.","journal-title":"CEN Case Rep"},{"key":"843_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2017.12.033","volume":"478","author":"AP Moura","year":"2018","unstructured":"Moura AP, Hammerschmidt T, Deon M, Giugliani R, Vargas CR. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease. Clin Chim Acta. 2018;478:62\u20137.","journal-title":"Clin Chim Acta"},{"key":"843_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107585","volume":"139","author":"A Burlina","year":"2023","unstructured":"Burlina A, Brand E, Hughes D, Kantola I, Kr\u04d3mer J, Nowak A, et al. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol Genet Metab. 2023;139: 107585.","journal-title":"Mol Genet Metab"},{"key":"843_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2169\/internalmedicine.3813-19","volume":"59","author":"Y Aoyama","year":"2020","unstructured":"Aoyama Y, Ushio Y, Yokoyama T, Taneda S, Makabe S, Nishida M, et al. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease. Intern Med. 2020;59:971\u20136.","journal-title":"Intern Med"},{"key":"843_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10157-022-02287-w","volume":"27","author":"M Nasu","year":"2023","unstructured":"Nasu M, Nakagawa N, Hara S, Yano J, Kurokawa Y, Nakamura N, et al. A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry. Clin Exp Nephrol. 2023;27:141\u201350.","journal-title":"Clin Exp Nephrol"},{"key":"843_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/ehjci\/jeab214","volume":"23","author":"DY Lu","year":"2022","unstructured":"Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, et al. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:487\u201395.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"1075639","DOI":"10.3389\/fcvm.2022.1075639","volume":"9","author":"M Umer","year":"2022","unstructured":"Umer M, Kalra DK. Cardiac MRI in Fabry disease. Front Cardiovasc Med. 2022;9:1075639.","journal-title":"Front Cardiovasc Med"},{"key":"843_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","volume":"99","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, et al. A validated disease severity scoring system for Fabry disease. Mol Genet Metab. 2010;99:283\u201390.","journal-title":"Mol Genet Metab"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00843-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:51:50Z","timestamp":1730919110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00843-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00843-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee, and with the 1964 Helsinki Declaration and its later amendments and comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}